Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.49 |
| ▸ | DGAT2 | Q96PD7 | 13/20 | 0.49 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.46 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.46 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1625269 | 0.99 | NOTUM (0.49) | NOTUMDGAT2PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL1624849 | 0.96 | DGAT2 (0.54) | NOTUMDGAT2PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL1625121 | 0.95 | PRKAG1 (0.49) | NOTUMDGAT2PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL1623335 | 0.94 | MAPT (0.49) | NOTUMDGAT2PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL1623246 | 0.94 | MAPT (0.49) | NOTUMDGAT2PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL1625355 | 0.94 | MAPT (0.43) | NOTUMDGAT2PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL1284103 | 0.94 | CCNC (0.48) | NOTUMDGAT2PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL1283986 | 0.93 | NOTUM (0.51) | NOTUMDGAT2PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL1624550 | 0.90 | NOTUM (0.51) | NOTUMPRKAG1PRKAA1PRKAB1MAPT | |
| SCHEMBL1624664 | 0.89 | NOTUM (0.52) | NOTUMDGAT2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835648-B2 | Hedgehog pathway antagonists and therapeutic applications thereof | SIENA BIOTECH S.P.A. (IT) | 2014-09-16 | — | — | US | disclosed |
| US-8835648-B2 | Hedgehog pathway antagonists and therapeutic applications thereof | SIENA BIOTECH S.P.A. (IT) | 2014-09-16 | — | — | US | disclosed |
| US-20120088752-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2012-04-12 | — | — | US | disclosed |
| US-20120088752-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088752-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SHH, GLI1, SMO | NOTUM 4463/4885DGAT2 719/4885PRKAG1 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.